Xilio Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $60.7M
- Price
- $9.23
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.72%
- Volume
- 5.2K
About
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
Quick stats
Shares outstanding6.6M
Computed float2.4M
Float / shares37.1%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001840233
Websitehttps://www.xiliotx.com
AI Summary
AI-generated1/9
majorbullishearnings
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Xilio Therapeutics received FDA clearance for the IND of its lead asset XTX501, with dosing in the Phase 1/2 trial expected to begin in the second half of 2026. The company reported Q2 2026 revenue of $18.7 million, more than doubling the prior year's figure, driven by its partnerships with AbbVie and Gilead.
The net loss narrowed significantly to $6.4 million, down from $15.8 million in the prior year quarter, supported by controlled R&D spending. Xilio ended the quarter with $136.0 million in cash, providing a runway into the first quarter of 2028 before considering potential warrant proceeds.
Pipeline progress includes advancing IND-enabling studies for masked T cell engagers targeting CLDN18.2 and PSMA+STEAP1, with submissions planned for the second half of 2027. Ben Harshbarger was also appointed as chief legal officer.
Red flags
- Reverse stock split of 1-for-14 effected in March 2026